Knight Therapeutics Reports First Quarter 2021 Results
MONTREAL, May 14, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2021 […]
Knight Therapeutics Inc. announces voting results from the Annual Meeting
MONTREAL, May 13, 2021 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held virtually in Montreal, Quebec (“Meeting”). Election of Directors Each director nominee listed in the Management Information Circular dated April 14, 2021 (“Circular”) […]
Knight Therapeutics Announces Leadership Change
– GUD to Great – MONTREAL, May 13, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) is pleased to announce that Samira Sakhia will assume the role of President and Chief Executive Officer, Knight Therapeutics Inc., effective September 1, 2021. Ms. Sakhia currently serves as Knight's President and Chief Operating Officer. Jonathan Ross Goodman will […]
Knight to Present at the 2021 RBC Capital Markets Global Healthcare Conference
MONTREAL, May 12, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 8:35 am ET. A […]
Notice of Knight Therapeutics’ First Quarter 2021 Results Conference Call
MONTREAL, May 07, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2021 financial results on Friday, May 14, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Therapeutics to Acquire Regional Rights to Exelon®
MONTREAL, April 23, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) a pan-America (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America (the “Territory“), as well […]
Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference
MONTREAL, April 13, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 9:30 a.m. ET that will […]
Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results
MONTREAL, March 25, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. […]
Notice of Knight Therapeutics’ Fourth Quarter 2020 Results Conference Call
MONTREAL, March 18, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter 2020 financial results on Thursday, March 25, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ – New Innovative Treatment for Irritable Bowel Syndrome with Constipation
MONTREAL, March 01, 2021 — Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of […]
